Test a minimally invasive add-on treatment for brain vessel swelling
Treatments studied
Part of Brain & nervous system, Heart & circulation, Injuries & trauma clinical trials.
This trial studies whether an add-on, minimally invasive procedure works better than standard care for a specific brain blood-vessel problem (CSH) that is larger than 10 mm. It may help reduce symptoms or prevent worsening, if you meet the size and location requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your brain CSH is confirmed by a CT scan (NCCT) and is larger than 10 mm.
- The CSH is located on the outer surface of the brain (the convexity).
- You have health insurance coverage that allows you to join the study.
- You do not have major reasons you can’t safely undergo the catheter/angiogram procedure (for example, severe kidney problems or a serious allergy).
- You don’t have severe disability before this illness (baseline mRS score of 3 or less) and you are not expected to live less than 6 months for reasons unrelated to CSH.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new, step-by-step care plan (called an enhanced recovery pathway) for people who need a small hole drilled in their skull to drain a slow-growing blood clot (chronic subdural hematoma). The goal is to see if this organized approach helps patients recover faster and feel better.
This trial compares two ways to treat a chronic subdural hematoma (a long-lasting bleed between the brain and its covering): blocking a specific artery versus standard surgery to remove the blood. It may help you and your care team choose the safer and more effective option for your situation.
This trial studies a procedure called middle-meningeal-artery embolization, which blocks the blood supply to a chronic subdural hematoma (a slow-growing blood collection around the brain). It compares outcomes in people with one-sided versus both-sided bleeds, and aims to see if this less invasive treatment can help reduce the need for surgery or improve recovery.
This trial tests whether adding a drug called bevacizumab (given through an artery in the brain) to a standard procedure called middle meningeal artery embolization (MMAE) helps treat chronic subdural hematoma (a collection of blood on the brain's surface) better than the procedure alone. The study is for people scheduled for MMAE who meet specific size and symptom criteria.
This trial compares a newer, less invasive treatment (embolization) with traditional surgery to treat chronic subdural hematoma (a slow bleed on the brain). It aims to see which approach works better and has fewer side effects.
This trial tests a procedure called middle meningeal artery embolization, which aims to stop the bleeding and reduce the fluid buildup from a chronic subdural hematoma. It may be an option for patients who have a hematoma at least 10mm thick and one or more risk factors such as older age, blood thinners, diabetes, or certain scan features.
Hear when a new Chronic Subdural Hematoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.